The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient’s clinical information and histopathology biopsy image to produce a personalized risk estimate of the patient’s likelihood of prostate cancer-specific mortality. This algorithmic insight addresses a significant gap in the treatment landscape for the approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the U.S. each year. By combining Tempus’ genomic-based next-generation sequencing (NGS) assay results with Artera’s pathology-based AI results, clinicians gain a far more comprehensive assessment of a patient’s prostate cancer disease.
Clinicians will be able to order the ArteraAI Prostate Test (mHSPC) as an add-on to Tempus’ solid tumor portfolio across all ordering modalities.
“From the start of our Tempus collaboration, our goal has been to deliver Artera’s AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way,” said Amanda Lowe, Chief Commercial Officer at Artera. “We’re excited that the newest product line extension of our ArteraAI Prostate Test, designed specifically for metastatic hormone-sensitive prostate cancer patients, will now be easily accessible throughout the Tempus ecosystem.”“Our mission is to bring actionable, data-driven insights directly to the point of care so clinicians can make more confident treatment decisions,” said Laura Elster, Chief Commercial Officer of Diagnostics at Tempus. “By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy, helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey.”
Source: BUSINESS WIRE. (2026). Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use [Press release]. https://www.businesswire.com/news/home/20260521525899/en/Tempus-Launches-ArteraAI-Prostate-Test-for-Metastatic-Patients-Marking-the-First-Prostate-Digital-Pathology-Algorithm-in-the-Tempus-Ecosystem-Available-for-Clinical-Use.